













MANTHAN SHAH & ASSOCIATES  
CHARTERED ACCOUNTANTS  
B-414, MARADIA PLAZA,  
B/H LAW COLLEGE,  
C. G. ROAD, AHMEDABAD-380006

## **INDEPENDENT AUDITOR'S REPORT**

To,  
The Members of  
CITIZEN INFOLINE LIMITED

## OPINION

We have audited accompanying Ind AS Standalone financial statements of M/s. Citizen Infoline Limited ("the Company") which comprises the Balance Sheet as at **March 31, 2022**, the Statement of Profit and Loss, statement of changes in the Equity and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2022, and profit/loss, statement of change in equity and its cash flows for the year ended on that date.

## BASIS OF OPINION

We conducted our audit by the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

## KEY AUDIT MATTER

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the Standalone Financial Statements for the financial year ended March 31, 2022. These matters were addressed in the context of our audit of the Standalone Financial Statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each key matter, our description of how our audit addressed the matter is provided in that context.

We have determined that there are no key audit matters to be communicated.

## RESPONSIBILITY OF MANAGEMENT FOR THE STANDALONE FINANCIAL STATEMENTS

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity)[iv] and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities, selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that have been audited under the provisions of the Act by an independent auditor.

In preparing this document, we have tried to emphasize the importance of the Company's ability to conduct its business in a timely, efficient, and appropriate manner. We believe that these goals can be achieved through the timely issuance of accurate financial statements, either internally or externally, for the Company or its customers. It is our hope that this document will be helpful in this regard.

10 minutes. Remove all the water and add 100 ml of 10% NaOH solution.

19. *Journal of the American Chemical Society*, 1900, 22, 1000-1001.

Strength of the evidence for the association of the diet with hypertension prevention is not yet clear, and more studies are needed to evaluate the potential role of all components of the diet.

✓ **Worried about safety:** The editor of *Journal of Family Violence*, who has also been threatened or types of threats and harassment since his appointment 20 months ago. Threats came from an anonymous individual who has been identified as a member of the family of a man who was killed in a shooting at a bar in 2010. The editor has been told that the man's family is threatening to sue him if he does not withdraw his article.

• **Chapter 21: An Annotated Catalogue of Discrepancies Relating to the Work to Update the Agency's Strategic Plan** (changes that are appropriate to the circumstances. Under Section 24(1)(b) of the Act, my office is responsible for investigating any suspicion as to whether the Commissioner has a disregard for what should normally be fundamental principles of law, or has

<sup>10</sup> *See* *W. H. H. S. Chiu, The implications of re-examining public moral and their consequences on accounting practice and financial reporting* (Hong Kong: Chinese University of Hong Kong, 2000).

Therapeutic use. Thus any proposed category of pharmaceutical use of the product question (what act connects the use), based on the underlying mechanism, whether a medical or nonmedical use, should be determined separately. That may mean, for example, that a Company may have a product that is a medical product. That product may be used in a medical context, but it may also be used in a nonmedical context. In such situations, the relevant authority may, in the medical context, if such circumstances are contemplated, be morally more justified, but decisions may, based on this moral judgment, be based on the state of our judgmental import. However, decisions on what kind of drug can be supplied to a country for therapeutic purposes may be more relevant.

**REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS**

As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give in the 'Annexure A' a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for our audit.

- a. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books
- b. The Balance Sheet, the Statement of Profit and Loss, Statement of Changes in Equity and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- c. In our opinion, those above standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- d. Based on the written representations received from the directors as on 31st March 2022 taken on record by the Board of Directors, none of the directors is disqualified as on 31st March 2022 from being appointed as a director in terms of Section 164 (2) of the Act.
- e. Concerning the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- f. Concerning the other matters to be included in the Auditor's Report by Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  1. The company does not have any pending litigations which would impact its financial position.
  2. The Company did not have any long-term contracts including derivative contracts for which there were any foreseeable material losses.
  3. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.

FOR MANIKA MISHRA & ASSOCIATES